Ambrx
Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan.
Overview
Ambrx is an organisation based in La Jolla, United States, founded in 2003 (Wikidata Q100955904, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. In OnCo it sponsors ACE-Breast-02 (phase 3, with Zhejiang Medicine: ARX788 against lapatinib plus capecitabine in HER2-positive advanced breast cancer after trastuzumab and a taxane, recorded as positive) and NCT04829604 (ACE-Breast-03, phase 2, ARX788 in HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan). ARX788 is its own compound, the basis for the biotech type.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
- registry trials +6
ARX788 is a HER2 ADC with a precisely placed, non-cleavable payload that beat lapatinib-capecitabine in China and showed activity in brain metastases.
Similar pages
not linked directly; found by shared links- CompanyCriterium
Shares HER2-positive breast cancer and the tag wave5-sponsor.
- TechnologySite-specific conjugation & linker chemistry
Shares ACE-Breast-02, ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03), ARX788, HER2-positive breast cancer.
- TreatmentZanidatamab zovodotin
Shares HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- PersonShanu Modi
Shares HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- TreatmentTrastuzumab duocarmazine
Shares HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- CompanyPrecirix
Shares HER2, HER2-positive breast cancer.
- PersonIan E. Krop
Shares HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- CompanyIksuda Therapeutics
Shares HER2, Antibody-drug conjugate (ADC).